Creating a treatment for severe cannabis-related health issues
Official title: Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndrome
Funded at Anebulo Pharmaceuticals, INC. · NIH-10829768 · Data updated 2026-11-12
This study is testing a new IV medication that could help people, both adults and kids, who are feeling really sick from using cannabis, by easing their nausea and vomiting in emergency rooms.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Anebulo Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Lakeway, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $892,290 |
| NIH project number | 1U01DA059995-01 |
| Project ID | NIH-10829768 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals of all ages who are experiencing acute cannabinoid intoxication or cannabis hyperemesis syndrome.
✕Less likely to help
Patients who do not use cannabis or who have unrelated gastrointestinal issues may not benefit from this research.
What this research studies
This research focuses on developing an intravenous medication that blocks the CB1 receptor to help patients suffering from acute cannabinoid intoxication and cannabis hyperemesis syndrome. The approach involves testing this new treatment in emergency settings where patients experience severe nausea, vomiting, and other distressing symptoms after cannabis use. By targeting the CB1 receptor, the research aims to alleviate these symptoms and improve patient outcomes. The study will involve both adult and pediatric patients who present with these conditions in emergency departments.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for individuals experiencing severe reactions to cannabis.
How similar studies have gone: While there has been some research on cannabinoid effects, this specific approach to developing a CB1 antagonist for these acute conditions is novel and has not been extensively tested.
Where this research is happening
-
Anebulo Pharmaceuticals, INC.
Lakeway, United States Active
Researchers
- Principal investigator: Cundy, Kenneth — Anebulo Pharmaceuticals, INC.
- Study coordinator: Cundy, Kenneth
Related research
Other NIH-funded projects on the same topics.
-
Hemp-derived CBD for reducing cannabis use in high-THC concentrate users
A randomized, placebo-controlled trial tests whether hemp-derived CBD can help adults who mainly use high-potency cannabis concentrates reduce their cannabis use.
-
Understanding how minority stress affects cannabis use in sexual minorities
A research project follows young adult sexual minorities to see how daily stress and coping help explain cannabis use and related problems.
-
Repeated cannabis with different THC/CBD mixes and how it affects pain, cravings, and body chemicals
This project studies how taking cannabis repeatedly, with different THC and CBD amounts, changes pain experiences, potential for abuse, and levels of body chemicals related to the endocannabinoid system in adults.
-
Terminal cannabinoid CB1 receptor changes in schizophrenia and cannabis use
This grant studies how cannabis use and schizophrenia together affect a brain receptor (CB1) and what that could mean for memory and symptoms.
-
Cannabis policies and prenatal cannabis use: how laws affect moms and babies
This grant studies how changes in recreational cannabis laws influence cannabis use during pregnancy and health outcomes for mothers and children.
-
Youth and social media marketing of hemp-derived cannabis products
Young people are increasingly exposed to hemp-derived cannabis product marketing on social media, and this study looks at how that marketing might influence their attitudes and curiosity.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.